Beam Therapeutics Inc. (BEAM)
NASDAQ: BEAM · Real-Time Price · USD
24.66
+0.44 (1.82%)
At close: Apr 2, 2026, 4:00 PM EDT
23.87
-0.79 (-3.21%)
After-hours: Apr 2, 2026, 7:54 PM EDT
Beam Therapeutics Employees
Beam Therapeutics had 511 employees as of December 31, 2025. The number of employees increased by 28 or 5.80% compared to the previous year.
Employees
511
Change
28
Growth
5.80%
Revenue / Employee
$273,470
Profits / Employee
-$156,540
Market Cap
2.45B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 511 | 28 | 5.80% |
| Sep 30, 2025 | 510 | 38 | 8.05% |
| Jun 30, 2025 | 509 | 48 | 10.41% |
| Mar 31, 2025 | 393 | 47 | 13.58% |
| Dec 31, 2024 | 483 | 47 | 10.78% |
| Sep 30, 2024 | 472 | 33 | 7.52% |
| Jun 30, 2024 | 461 | -71 | -13.35% |
| Mar 31, 2024 | 346 | -177 | -33.84% |
| Dec 31, 2023 | 436 | -71 | -14.00% |
| Sep 30, 2023 | 439 | -68 | -13.41% |
| Jun 30, 2023 | 532 | 56 | 11.76% |
| Mar 31, 2023 | 523 | 129 | 32.74% |
| Dec 31, 2022 | 507 | 166 | 48.68% |
| Sep 30, 2022 | 507 | 201 | 65.69% |
| Jun 30, 2022 | 476 | 210 | 78.95% |
| Mar 31, 2022 | 394 | 178 | 82.41% |
| Dec 31, 2021 | 341 | 160 | 88.40% |
| Sep 30, 2021 | 306 | 140 | 84.34% |
| Jun 30, 2021 | 266 | 115 | 76.16% |
| Mar 31, 2021 | 216 | 98 | 83.05% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Zai Lab | 1,784 |
| Sarepta Therapeutics | 835 |
| Adaptive Biotechnologies | 624 |
| Ascentage Pharma Group International | 605 |
| Relay Therapeutics | 192 |
| Immunome | 177 |
| Disc Medicine | 155 |
| Kodiak Sciences | 124 |
BEAM News
- 3 days ago - Beam Therapeutics Announces Publication of BEACON Phase 1/2 Data for risto-cel in Patients with Sickle Cell Disease (SCD) in The New England Journal of Medicine - GlobeNewsWire
- 10 days ago - Beam Therapeutics Inc. (BEAM) Discusses Topline Phase I/II Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency Transcript - Seeking Alpha
- 11 days ago - Beam Therapeutics Gains On Clinical Update As Gene Therapy Hits Protective Protein Levels - Benzinga
- 11 days ago - Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal Development - GlobeNewsWire
- 5 weeks ago - Beam Therapeutics: Great Potential, But Patience Is Needed - Seeking Alpha
- 5 weeks ago - Beam Therapeutics Inc. (BEAM) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 5 weeks ago - What's Going On With Beam Therapeutics Stock? - Benzinga
- 5 weeks ago - Beam Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Announces New Liver-Targeted Genetic Disease Program in Phenylketonuria (PKU) - GlobeNewsWire